Drugs / JNJ-64457744
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05423106 | Jul 2022 → Mar 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64457744 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05423106 ↗ |
| Route | Oral | “JNJ-64457744 will be administered as oral solution.” NCT05423106 ↗ |